0

SCI Publications

Gut Skin Axis

0 %

High Survival Rate

*more than 80% market share in Taiwan since 2018
0
Years
of Research for Gut Skin Harmony

Vigiis® 101-LAB (Lactobacillus paracasei subsp. paracasei NTU 101) was discovered by National Taiwan University after screening hundreds of bacterial strains. Supported by 40 SCI publications, this clinically proven probiotic boasts an impressive 95% survival rate against gastric acid and bile salts. It serves as a revolutionary solution, specifically crafted for relieving symptoms of atopic dermatitis.

  • Drug-resistant gene-free and genetically stable
  • Survives gastrointestinal conditions with strong adherence capability
  • Backed by multiple clinical trials and scientific evidence for digestive and skin health

Gut-Skin Axis

The emerging concept of the gut-skin axis highlights the bidirectional relationship between the gut microbiome and skin health. Atopic dermatitis (AD), a chronic inflammatory skin disorder, significantly impacts quality of life. Increasing evidence suggests that modulating the gut microbiota with probiotics can help maintain skin health—further supporting the crucial role of the gut-skin axis.

Maintaining Healthy Skin from the Inside Out

By balancing the gut flora, Vigiis® 101-LAB not only enhances overall immunity for atopic dermatitis, it effectively promote the generation of regulatory T cells (Treg), as well as Th1/Th2 balance, which play a crucial role in regulating immune responses. This helps reduce excessive immune reactions and inflammation, thereby maintaining healthy skin from the inside out.

This is where it started……
This is where it started……

After 8 weeks of daily supplementation with Vigiis® 101-LAB, one individual reported noticeable changes around the ear. This aligns with growing scientific insights into the role of the gut-skin axis—highlighting how a healthy gut microbiome may support skin health from the inside out.*

If my research can make a difference in people's lives, then by all means, go for it.

John, SunWay President

Applications

Our comprehensive portfolio of global patents underscores our commitment to innovation and ensures that our clients’ investments will significantly influence the market.

Market Insight

We’re proud to announce that our flagship probiotic strain — Lactobacillus paracasei NTU 101, marketed as #Vigiis101 — has officially received GRAS (Generally Recognized As Safe) status, GRN 001232, from the U.S. Food and Drug Administration (FDA). This is the first-ever GRAS recognition for L. paracasei from Taiwan, highlighting SunWay Biotech’s excellence in R&D and our strategic vision for the global probiotic market.
The first clinical study, which has been published in Heliyon, documents that Vigiis® 101-LAB significantly increases the bacterial counts of Bifidobacterium spp. and Lactobacillus spp. in feces in just one week, and maintains those elevated counts for four weeks.
Reference

1. In-house studies

Disclaimer

The communication is intended for business-to-business information and not for the final consumer. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Contact Us